Lexicon Pharmaceuticals (NASDAQ:LXRX) Stock Rating Reaffirmed by Needham & Company LLC

Lexicon Pharmaceuticals (NASDAQ:LXRX)‘s stock had its “hold” rating reiterated by stock analysts at Needham & Company LLC in a research report issued on Tuesday, Benzinga reports.

Separately, StockNews.com upgraded shares of Lexicon Pharmaceuticals to a “sell” rating in a research report on Monday, April 15th.

Lexicon Pharmaceuticals Stock Down 0.6 %

LXRX stock opened at $1.60 on Tuesday. The firm has a fifty day moving average price of $2.28 and a two-hundred day moving average price of $1.72. The firm has a market cap of $393.98 million, a price-to-earnings ratio of -2.00 and a beta of 1.27. The company has a debt-to-equity ratio of 1.07, a current ratio of 5.60 and a quick ratio of 5.58. Lexicon Pharmaceuticals has a 1-year low of $0.92 and a 1-year high of $3.79.

Lexicon Pharmaceuticals (NASDAQ:LXRX) last released its quarterly earnings results on Monday, March 11th. The biopharmaceutical company reported ($0.20) EPS for the quarter, topping the consensus estimate of ($0.23) by $0.03. The business had revenue of $0.70 million during the quarter, compared to analyst estimates of $0.68 million. Lexicon Pharmaceuticals had a negative net margin of 14,573.20% and a negative return on equity of 138.54%. Research analysts predict that Lexicon Pharmaceuticals will post -0.71 EPS for the current year.

Institutional Investors Weigh In On Lexicon Pharmaceuticals

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Victory Capital Management Inc. lifted its holdings in Lexicon Pharmaceuticals by 22.0% in the 4th quarter. Victory Capital Management Inc. now owns 32,187 shares of the biopharmaceutical company’s stock valued at $49,000 after acquiring an additional 5,813 shares during the last quarter. Swiss National Bank lifted its stake in Lexicon Pharmaceuticals by 4.4% during the third quarter. Swiss National Bank now owns 242,300 shares of the biopharmaceutical company’s stock valued at $264,000 after buying an additional 10,300 shares in the last quarter. Cantor Fitzgerald L. P. purchased a new stake in Lexicon Pharmaceuticals during the fourth quarter valued at about $25,000. Principal Securities Inc. purchased a new stake in Lexicon Pharmaceuticals during the fourth quarter valued at about $33,000. Finally, China Universal Asset Management Co. Ltd. lifted its stake in Lexicon Pharmaceuticals by 350.7% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 28,329 shares of the biopharmaceutical company’s stock valued at $43,000 after buying an additional 22,043 shares in the last quarter. 74.70% of the stock is owned by institutional investors and hedge funds.

About Lexicon Pharmaceuticals

Lexicon Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract.